Another Phase Ib/II trial exploring the safety and efficacy of capmatinib treatment with cetuximab, an anti-EGFR antibody, in HNSCC and metastatic colorectal cancers positive for c-MET has recently been suspended for unknown reasons (NCT02205398). Here, MET is linked to head and neck squamous cell carcinoma.